Feline coronavirus

Ainos Publishes Preclinical Data Demonstrating its VELDONA Formulation's Potential as Treatment Candidates for the Most Common Medical Conditions for Companion Animals

Retrieved on: 
Monday, November 21, 2022
SAN, VOC, POCT, Growth, RATS, Miniature pig, Mouse, Plasma protein binding, Feline coronavirus, Ciclosporin, Dog, Immunity, Therapy, Animal, Risk, Cat, Research, Saudi Research and Marketing Group, Cattle, Acceleration, US, EC50, Sale, Volatile organic compound, Market, Point-of-care testing, Roy Taylor (scientist), Guinea, Annual report, Subclinical infection, Horse, COVID-19, Human, AIMD, CAD, Prevalence, FCGS, Pharmaceutical industry, Vaccine, Pet, Ainos

SAN DIEGO, Nov. 21, 2022 /PRNewswire/ -- Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that it has published preclinical data demonstrating the potential of its low-dose oral interferon-alpha (IFNα) formulation, VELDONA®, as treatment candidates for the two most common medical conditions for dogs and cats. The preclinical data can be accessed here.

Key Points: 
  • The Company initially applied VELDONA to feline coronavirus (FCoV)-infected fcwf-4 (feline microphage) systems to determine potency and dose translation.
  • Based on VELDONA's effective antiviral efficacy,the Company is planning an expansion of its use for the treatment of humans to treatment of animals.
  • Ainos is designing dose-finding field studies to identify optimal VELDONA dose via oromucosal administration for feline FCGS and canine CAD.
  • FCGS is a severe oral mucosal inflammatory disease afflicting cats, while CAD is an inflammatory skin disease found in dogs.

LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test

Retrieved on: 
Friday, May 29, 2020
Medical Supplies, Biotechnology, FDA, Other Health, Health, General Health, Women, Seniors, MEN, Infectious diseases, Consumer, Viruses, Nidovirales, Animal virology, Coronaviridae, Zoonoses, Coronavirus, Severe acute respiratory syndrome-related coronavirus, Severe acute respiratory syndrome, Feline coronavirus, Middle East respiratory syndrome-related coronavirus

Offering an end-to-end model, LetsGetCheckeds new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution.

Key Points: 
  • Offering an end-to-end model, LetsGetCheckeds new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution.
  • The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours.
  • Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA.
  • The at-home Coronavirus test is accompanied by LetsGetCheckeds connected platform offering 24/7 telehealth services supported by licensed healthcare professionals and timely guidance on containment and care for those who test positive.

STI-1499, A Potent Anti-SARS-CoV-2 Antibody, Demonstrates Ability To Completely Inhibit In Vitro Virus Infection In Preclinical Studies

Retrieved on: 
Friday, May 15, 2020
Medical specialties, Branches of biology, Medicine, Antibodies, Immunology, Zoonoses, Glycoproteins, Severe acute respiratory syndrome-related coronavirus, Neutralisation, Severe acute respiratory syndrome, Feline coronavirus

These blocking antibodies were further tested for their ability to inhibit SARS-CoV-2 virus infection in an in vitro SARS-CoV-2 virus infection model pursuant to a preclinical testing agreement for COVID-19 therapeutic candidates that was previously announced on March 31, 2020 ( Sorrento Therapeutics ).

Key Points: 
  • These blocking antibodies were further tested for their ability to inhibit SARS-CoV-2 virus infection in an in vitro SARS-CoV-2 virus infection model pursuant to a preclinical testing agreement for COVID-19 therapeutic candidates that was previously announced on March 31, 2020 ( Sorrento Therapeutics ).
  • Among the antibodies showing neutralizing activity, one antibody stood out for its ability to completely block SARS-CoV-2 infection of healthy cells in the experiments.
  • STI-1499 completely neutralized the virus infectivity at a very low antibody dose, making it a prime candidate for further testing and development.
  • Sorrento has determined STI-1499 will likely be the first antibody in the antibody cocktail (COVI-SHIELD) it is developing, as recently announced.

Vyriad Inc. Announces Development of a New Antibody Test to Determine Protective Immunity From COVID-19

Retrieved on: 
Tuesday, May 12, 2020
Viruses, Branches of biology, Medicine, Zoonoses, Severe acute respiratory syndrome-related coronavirus, Glycoproteins, Antibodies, Severe acute respiratory syndrome, Neutralizing antibody, Feline coronavirus

The Vyriad SARS-CoV-2 Neutralizing Antibody Test detects neutralizing antibodies, the critical subset of antibodies known to protect against SARS-CoV-2 viral infections.

Key Points: 
  • The Vyriad SARS-CoV-2 Neutralizing Antibody Test detects neutralizing antibodies, the critical subset of antibodies known to protect against SARS-CoV-2 viral infections.
  • Vyriad and Regeneron jointly developed the test as part of their existing discovery and development collaboration .
  • The Vyriad SARS-CoV-2 Neutralizing Antibody Test uses an innocuous virus that has been engineered to carry this SARS-CoV-2 spike glycoprotein on its surface.
  • This collaboration now includes the SARS-CoV-2 Neutralizing Antibody Test, which was developed utilizing the deep scientific expertise of both companies.

Coronavirus Research Database Gives ProQuest Users No-Cost Access to Essential Coverage of COVID-19 and More

Retrieved on: 
Tuesday, March 31, 2020
Viruses, Animal virology, Coronaviridae, Zoonoses, Coronavirus, ProQuest, Severe acute respiratory syndrome, Ex Libris Group, Feline coronavirus

Journals, preprints, conference proceedings and dissertations provide comprehensive coverage ofCOVID-19 and other past coronavirus outbreaks, such as MERS and SARS, for context around the current global pandemic.

Key Points: 
  • Journals, preprints, conference proceedings and dissertations provide comprehensive coverage ofCOVID-19 and other past coronavirus outbreaks, such as MERS and SARS, for context around the current global pandemic.
  • Full-text content in the database is available either directly from ProQuest or via links to publisher sites.
  • "The Coronavirus Research Database was created as a tool to help our usersto find the information they need to quickly explore the many facets of this disease."
  • Along with its companies and affiliates Ex Libris, Alexander Street and Bowker, ProQuest helps its customers achieve better research, better learning and better insights.

Vir Biotechnology Identifies Two Antibodies That Bind to the Spike Protein of 2019-nCoV, Newly Named as SARS-CoV-2

Retrieved on: 
Wednesday, February 12, 2020
Viruses, Nidovirales, Animal virology, Coronaviridae, Coronavirus, Severe acute respiratory syndrome-related coronavirus, Immunology, Antibodies, Neutralisation, Middle East respiratory syndrome-related coronavirus, Feline coronavirus

The antibodies target the SARS-CoV-2 spike protein in the region that the virus uses to enter cells through the cellular receptor ACE2.

Key Points: 
  • The antibodies target the SARS-CoV-2 spike protein in the region that the virus uses to enter cells through the cellular receptor ACE2.
  • We are in the process of assessing neutralization with a pseudo-virus, said George Scangos, Ph.D., CEO of Vir.
  • In addition, we are working with international partners to assess the capacity of these antibodies to neutralize the live virus, SARS-CoV-2.
  • Vir identified these antibodies from an existing library of 20 fully human antibodies that bind and neutralize related coronaviruses, such as SARS-CoV and coronaviruses that infect animals.